However, its use solely for weight loss in non-diabetics should be carefully considered and supervised by a healthcare provider
Key results: On-treatment (no interruptions): Semaglutide (Wegovy): 57% lower risk of heart attack, stroke, or death Tirzepatide: Reference comparator Including treatment gaps: Semaglutide: 29% lower risk of major adverse cardiovascular events Tirzepatide: Higher event rates in this real-world analysis Why this matters: These data suggest semaglutide may have greater cardiovascular benefit than tirzepatidea provocative finding given both are highly effective for weight loss
Rule Out Underlying Issues Persistent hunger may be a sign of hormonal imbalances, emotional stress, or other health conditions
Retatrutide is a synthetic peptide based on a glucose-dependent insulinotropic polypeptide (GIP) backbone, but uniquely, it functions as a triple agonist
If your primary symptom is joint pain with stiffness, a short course of NSAIDs may be appropriate, but consult your healthcare provider first
No step can be skipped
